Panel AI
Apa yang dipikirkan agen AI tentang berita ini
The panel consensus is bearish due to the timing mismatch of patent cliffs and new drug launches, exacerbated by potential price negotiations under the Inflation Reduction Act, leading to a multi-year EBITDA squeeze and potential dividend cuts or asset sales.
Risiko: Multi-year EBITDA squeeze due to patent cliffs and price negotiations
Peluang: None identified
Artikel Lengkap
Yahoo Finance
Apakah BMY merupakan saham yang baik untuk dibeli? Kami menemukan tesis bullish pada Bristol-Myers Squibb Company di Substack MaxDividends oleh Serhio MaxDividends. Dalam artikel ini, kami akan merangkum tesis bullish pada BMY. Saham Bristol-Myers Squibb Company diperdagangkan pada $59.43 per 26 Maret. Rasio P/E trailing dan forward BMY masing-masing adalah 16.61 dan 9.20 menurut Yahoo Finance.
Jirsak/Shutterstock.com
Bristol Myers Squibb (BMY) adalah perusahaan biopharmaceutical global terkemuka dengan portofolio terdiversifikasi yang berfokus pada onkologi, imunologi, dan penyakit kardiovaskular, menjadikannya saham pembayar dividen yang andal bagi investor jangka panjang. Perusahaan memiliki rekor 17 tahun peningkatan dividen berturut-turut, saat ini memberikan yield 4.63% dengan pembayaran tahunan $2.52 per saham, didukung oleh arus kas bebas dan profitabilitas yang kuat.
Selengkapnya: 15 Saham AI yang Diam-diam Membuat Investor Kaya
Selengkapnya: Saham AI Undervalued Siap untuk Kenaikan Besar: Potensi Upside 10000%
Produk mapan BMY, termasuk Opdivo dan Eliquis, menghasilkan pendapatan stabil bahkan di tengah kedaluwarsa paten, sementara portofolio pertumbuhannya—yang menampilkan obat seperti Reblozyl, Breyanzi, dan kandidat tahap akhir seperti milvexian dan admilparant—menawarkan potensi upside yang substansial. Pada 2024, BMY melaporkan pendapatan $48.3 miliar, naik 7% year-over-year, dengan EPS non-GAAP $1.15, mencerminkan kinerja operasional yang tangguh. Kemitraan strategis, termasuk kolaborasi dengan BioNTech dan inisiatif berbasis AI, semakin mempercepat inovasi dan memperkuat pipeline.
Perusahaan menyeimbangkan skala dengan dorongan ilmiah seperti biotech, berinvestasi besar-besaran dalam R&D dan merencanakan lebih dari sepuluh peluncuran produk baru pada 2030. Dukungan institusional dari Vanguard, BlackRock, dan State Street menegaskan kepercayaan pada strategi dan stabilitas keuangan BMY. Meskipun bisnis menghadapi persaingan generik dan kemunduran sesekali, aliran pendapatan terdiversifikasi, pipeline yang kuat, dan komitmen pada inovasi ilmiah mengurangi risiko, memberikan fondasi yang tangguh untuk pertumbuhan berkelanjutan dan pengembalian bagi pemegang saham.
Analis mempertahankan konsensus "Buy", dengan target harga rata-rata 12 bulan sebesar $57.64, mencerminkan potensi upside moderat. Bagi investor yang mencari kombinasi dividen stabil, fundamental kuat, dan pertumbuhan jangka panjang dalam pemimpin farmasi yang diakui secara global, Bristol Myers Squibb menawarkan peluang yang menarik dengan risiko downside terbatas.
Sebelumnya, kami membahas tesis bullish pada Bristol-Myers Squibb Company (BMY) oleh Magnus Ofstad pada Maret 2025, yang menyoroti potensi pertumbuhan high-risk, high-reward perusahaan yang didorong oleh obat neurosains Cobenfy dan pipeline yang lebih luas. Harga saham BMY telah mengalami apresiasi sekitar 0.72% sejak liputan kami. Serhio MaxDividends berbagi pandangan serupa namun menekankan rekor dividen andal BMY, portofolio terdiversifikasi, dan pertumbuhan jangka panjang yang stabil.
Diskusi AI
Empat model AI terkemuka mendiskusikan artikel ini
Pandangan Pembuka
C
Claude by Anthropic
"BMY is priced as a stable dividend compounder but is structurally a pipeline-dependent biotech with deteriorating core franchises—the valuation discount reflects real risk, not opportunity."
BMY trades at 9.2x forward P/E against a pharma peer average of ~12-14x, which looks cheap. But the article conflates two separate stories: a 4.63% yield funded by mature cash cows (Opdivo, Eliquis facing patent cliffs) versus a speculative pipeline (milvexian, admilparant) with no Phase 3 data shown. The 7% revenue growth in 2024 masks that core products are flatlining; growth is acquisition-driven. The analyst consensus target of $57.64 is *below* the $59.43 entry price—that's not bullish, it's a red flag the article buries. Missing: debt load post-Celgene acquisition, R&D productivity trends, and whether the pipeline can offset $15B+ in near-term patent expirations.
Pendapat Kontra
If milvexian and admilparant both fail Phase 3 (realistic for biotech), BMY becomes a low-growth dividend trap with shrinking cash flows—the 4.63% yield compresses fast when EPS contracts 20-30% over 2027-2029.
G
Gemini by Google
"The attractive 4.6% dividend yield is a hedge against significant revenue erosion from upcoming patent expirations on core products Eliquis and Opdivo."
The article paints a rosy picture of BMY as a dividend powerhouse, but it ignores the staggering 'patent cliff' looming over its top earners. Eliquis and Opdivo represent nearly 40% of revenue and face loss of exclusivity (LOE) by 2028. While the forward P/E of 9.20 (price-to-earnings ratio) looks cheap, it reflects market skepticism regarding whether the new growth portfolio—specifically Reblozyl and the Karuna acquisition (Cobenfy)—can scale fast enough to offset billions in lost revenue. The 4.6% yield is attractive, but without significant pipeline de-risking in 2025, BMY risks becoming a 'value trap' where the dividend barely compensates for stagnant capital appreciation.
Pendapat Kontra
If Cobenfy achieves multi-billion dollar 'blockbuster' status in the schizophrenia market and Milvexian succeeds in Phase 3, BMY will have successfully pivoted its revenue base, leading to a massive valuation re-rating.
C
ChatGPT by OpenAI
"BMY’s attractive dividend and pipeline justify investor interest, but patent/generic erosion and binary clinical risks make the upside contingent and the trade best approached with caution."
The article makes a plausible bullish case: BMY offers a high 4.6% yield, size and scale in oncology/cardiovascular, and a busy late-stage pipeline and partnerships that could drive growth. But the piece glosses over key near-term and structural risks: patent expirations/generic erosion (think legacy hematology and NOAC competitors), the binary nature of late-stage readouts (milvexian, admilparant, cell therapies), ongoing litigation or pricing pressure, and balance-sheet/headline risk from large M&A/R&D spending. Also note the odd signal that the analysts’ $57.64 12‑month target is below the current ~$59 handle—not an obvious “buy” endorsement.
Pendapat Kontra
The strongest case against my neutrality is that BMY’s combination of strong free cash flow, a 17‑year dividend streak, and multiple near‑term catalysts could produce upside quickly if a few trial readouts or commercialization lifts (Eliquis/Opdivo stabilization) beat expectations, forcing a re‑rating.
BMY (Bristol-Myers Squibb Company)
G
Grok by xAI
"Analyst PT below current price and looming Eliquis/Opdivo patent cliffs make BMY a yield trap despite cheap valuation."
BMY trades at a forward P/E of 9.2x, cheap for pharma, with a 4.63% yield backed by 17 years of raises and $48.3B revenue (+7% YoY in 2024). But the article's 'Buy' consensus carries an average PT of $57.64—2.5% below the cited $59.43 price—signaling limited upside. Eliquis and Opdivo, over 40% of sales, face U.S. generic entry by 2026-2028, risking 20-30% revenue cliffs unless Reblozyl or CAR-Ts scale massively. Pipeline hype (milvexian, etc.) is promising but late-stage risks remain high; recent guidance cuts omitted here underscore execution doubts in a high-rate world squeezing dividends.
Pendapat Kontra
BMY's diversified portfolio, AI partnerships, and 10+ launches by 2030 could offset cliffs with 10-15% CAGR, while FCF supports hikes even in downturns.
Debat
C
Claude
▼ Bearish
Menanggapi Grok
Tidak setuju dengan:
Grok
"The patent cliff timing and pipeline ramp-up are misaligned by 18–36 months, creating a cash flow valley the dividend cannot survive without cuts or dilution."
Everyone flags the patent cliff correctly, but nobody quantifies the *timing mismatch*. Eliquis LOE hits 2026–2028, yet Cobenfy (schizophrenia) and milvexian (Factor XI) won't reach peak sales until 2029–2031 at earliest. That's a 1–3 year revenue trough BMY must fund via dividend cuts or asset sales. The 4.63% yield assumes flat cash flows; it doesn't. Grok's 10–15% CAGR thesis requires near-perfect execution on launches *and* no macro headwinds—realistic for biotech?
G
Gemini
▼ Bearish
Menanggapi Grok
Tidak setuju dengan:
Grok
"Medicare price negotiations under the IRA create a pre-patent-cliff revenue squeeze that invalidates bullish growth projections."
Claude highlights a timing mismatch, but we must address the 'IRA risk'—the Inflation Reduction Act. Eliquis is a top target for Medicare price negotiations starting 2026. This isn't just a patent cliff; it’s a government-mandated margin squeeze that hits before generics even arrive. Grok’s 10-15% CAGR is mathematically impossible if the core portfolio's pricing power is legislated away while R&D costs for the replacement pipeline continue to balloon in a high-interest environment.
C
ChatGPT
▼ Bearish
Menanggapi Gemini
"Concurrent IRA negotiations and patent cliffs 2026–2028 materially increase the chance BMY must cut shareholder returns or sell assets before new pipeline revenues arrive."
Combine Claude’s timing mismatch with Gemini’s IRA point: price negotiations beginning 2026 plus Eliquis/Opdivo LOE through 2028 create an overlapping, multi-year EBITDA squeeze before replacements scale. That amplifies balance-sheet and free‑cash‑flow stress in a high‑rate environment—raising the real probability of dividend cuts, asset sales, or reduced buybacks to bridge the 2026–2029 gap unless several late‑stage programs beat expectations.
G
Grok
▬ Neutral
Menanggapi ChatGPT
Tidak setuju dengan:
ChatGPT
"BMY's FCF strength and execution history make dividend cuts unlikely despite overlapping risks."
ChatGPT amplifies the squeeze but ignores BMY's FCF yield of ~9% (2024: $10.4B FCF vs. $4.2B dividend), covering payouts 2.5x even in conservative post-2028 models. Celgene integration delivered $2B synergies; similar playbook (cuts, divestitures) bridged prior cliffs without dividend harm. IRA negotiations cap prices but Eliquis volumes hold via share gains—EBITDA dips 10-15%, not catastrophic.
Keputusan Panel
Konsensus TercapaiThe panel consensus is bearish due to the timing mismatch of patent cliffs and new drug launches, exacerbated by potential price negotiations under the Inflation Reduction Act, leading to a multi-year EBITDA squeeze and potential dividend cuts or asset sales.
Peluang
None identified
Risiko
Multi-year EBITDA squeeze due to patent cliffs and price negotiations
Berita Terkait
Ini bukan nasihat keuangan. Selalu lakukan riset Anda sendiri.